

## Bulky Pelvic Hodgkin Lymphoma in a Prepubertal Girl

### Abstract

Pure infra-diaphragmatic presentation is rare in pediatric Hodgkin lymphoma (HL). Isolated pelvic presentation is restricted to case reports in adults. We describe a unique presentation of HL as a primary pelvic disease in an 11-year-old prepubertal girl. She was treated based on the Euronet-Paediatric Hodgkin's Lymphoma Group protocol (EuroNet-PHL-C1) recommendations and assigned to treatment Group 2 (Stage IIB). The patient had bulky disease and a suboptimal response on interim 18-fluorodeoxyglucose positron emission tomography. The child was administered chemotherapy alone. Pelvic radiotherapy was consciously avoided due to the high risk of gonadal failure. She remains disease-free for 18 months now. Treatment of pediatric HL necessitates a delicate balance between achieving cure as well as avoiding serious late effects of therapy.

**Keywords:** Hypogonadism, infradiaphragmatic, late effects, positron emission tomography scan, radiation

### Introduction

Primary sub-diaphragmatic pediatric Hodgkin lymphoma (HL) comprises merely 3% of all pediatric cases.<sup>[1]</sup> Isolated HL in the pelvis is rarely reported.<sup>[2,3]</sup> We report a prepubertal girl with a pelvic mass, which uniquely turned out to be HL. Besides chemotherapy, the management involved debating pros and cons of administering radiotherapy to the sensitive site.

### Case Report

An 11-year-old girl presented with fever for 4 months. On examination, a left-sided suprapubic mass was palpated. Ultrasonography confirmed a mass in the pelvis. A magnetic resonance imaging revealed a large mass located in the pelvis, along with enlarged lymph nodes [Figure 1]. The initial clinical possibility was of a gonadal germ cell tumor. Serum alpha-fetoprotein and beta-human chorionic gonadotrophin were normal. A core biopsy was consistent with a diagnosis of HL, nodular sclerosis (NS) type. Immunohistochemistry was confirmatory; the large atypical cells were positive for CD15/CD30 and negative for CD20. An 18-fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET-CT) confirmed

FDG avidity of the mass and adjoining nodes. The bone marrow was not infiltrated.

The patient was assigned to stage IIB and treatment - Group-2 of the Euronet-Paediatric Hodgkin's Lymphoma Group protocol (EuroNet-PHL-C1).<sup>[4]</sup> Two cycles of O-vincristine, E-etoposide, P-prednisone, A-adriamycin were administered. An interim FDG-PET-CT revealed >50% reduction of the mass, with a Deauville score (DS) of three, with complete resolution of the nodes. As per the guidelines of EuroNet-PHL-C1 trial, with a local partial remission and a DS of three, radiotherapy was indicated following two cycles of C-cyclophosphamide, O-vincristine, P-prednisone, DAC-dacarbazine (COPDAC). However, there was a major concern for infertility with radiotherapy to the pelvis. The multi-disciplinary team, along with the parents debated the options. The emerging international consensus was of DS of 1–3 being considered as a complete metabolic response at early interim PET.<sup>[5]</sup> Indeed, in the succeeding Euronet-C2 trial, the threshold of radiotherapy was to be raised to DS of 4–5, instead of 3–5.<sup>[6]</sup> The team opted to avoid radiotherapy and administer two additional (total: four) cycles of COPDAC, instead. An ultrasonography performed following six cycles of chemotherapy revealed a small cystic residual mass in the region of the left

**Sidharth Totadri,  
Deepak Bansal,  
Amanjit Bal<sup>1</sup>,  
Prema Menon<sup>2</sup>**

*Department of Pediatrics,  
Advanced Pediatrics Center,  
Pediatric Hematology-Oncology  
Unit, Departments of  
<sup>1</sup>Histopathology and <sup>2</sup>Pediatric  
Surgery, Postgraduate Institute  
of Medical Education and  
Research, Chandigarh, India*

### Address for correspondence:

*Dr. Deepak Bansal,  
Department of Pediatrics,  
Advanced Pediatrics Center,  
Pediatric Hematology-Oncology  
Unit, Postgraduate Institute  
of Medical Education and  
Research, Chandigarh, India.  
E-mail: deepakbansaldr@gmail.  
com*

### Access this article online

**Website:** www.ijmpo.org

**DOI:** 10.4103/ijmpo.ijmpo\_150\_16


### Quick Response Code:



**How to cite this article:** Totadri S, Bansal D, Bal A, Menon P. Bulky pelvic hodgkin lymphoma in a prepubertal girl. Indian J Med Paediatr Oncol 2017;38:226-7.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com



**Figure 1: Magnetic resonance imaging (a - sagittal view, b - coronal view) demonstrated a large pelvic mass (arrows in a and b). The left sided ovary was not distinctly identified. The uterus and urinary bladder were displaced and compressed by the mass**

adenexa. A diagnostic laparoscopy performed to visualize and biopsy the mass demonstrated trivial boggy soft tissue in the pelvic wall with no visible mass. She has been well and in follow-up for 18 months.

## Discussion

Primary infradiaphragmatic HL has been reported in 4%–13% of patients in studies encompassing all age groups.<sup>[7,8]</sup> Published literature on isolated pelvic disease is restricted to adults.<sup>[2,3]</sup> Infradiaphragmatic HL demonstrates distinct characteristics when compared to supradiaphragmatic disease such as older age, multiple involved sites, increased frequency of lymphocyte predominant histology, and a reduced frequency of NS variants.<sup>[7-10]</sup> Survival rates are not observed to be different, and recommendations for treatment do not differ.<sup>[4,7-9]</sup> Bulky disease with an inadequate response on interim FDG-PET is ideally radiated, albeit with increased risk of gonadal failure, premature menopause, and infertility in pelvic HL.<sup>[11]</sup> According to the Lugano classification for the management of lymphomas, DS-3 on interim FDG-PET indicates a favorable prognosis in most patients; interpretation must take into account timing of assessment, clinical context, and treatment.<sup>[5]</sup> We consciously avoided radiotherapy and administered two additional cycles of chemotherapy to avoid gonadal failure. A longer follow-up is necessary for ensuring a relapse-free period.

## Conclusions

Pelvic HL is a rarity in children. The decision for radiotherapy is arduous due to the risk of infertility.

## Acknowledgment

The inputs for management from Dr. Stephen Daw (Department Paediatric and Adolescent Oncology, University College London Hospital NHS Foundation Trust, London) and Dr. Rakesh Mittal (Ex-consultant, Kuwait Cancer Center, Ministry of Health, Kuwait) are gratefully acknowledged.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

## References

1. Metzger M, Krasin MJ, Choi JK, Hudson MM. Hodgkin lymphoma. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. 7<sup>th</sup> ed. Philadelphia: Williams and Wilkins; 2015. p. 568-86.
2. Kiran G, Canaz E, Sayar H, Serin S, Balakan O. Primary extranodal Hodgkin's lymphoma presenting with a single pelvic mass. *J South Asian Fed Obstet Gynaecol* 2014;6:183-6.
3. Ha-Ou-Nou FZ, Benjilali L, Essaoudouni L. Sacral pain as the initial symptom in primary Hodgkin's lymphoma of bone. *J Cancer Res Ther* 2013;9:511-3.
4. Available from: <https://www.skion.nl/workspace/uploads/EuroNet-PHL-Interim-Treatment-Guidelines-2012-12-3v0-2.pdf>. [Last cited on 2016 Aug 06].
5. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, *et al.* Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. *J Clin Oncol* 2014;32:3059-68.
6. Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents - Full Text View. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT02684708>. [Last cited on 2016 Aug 07].
7. Darabi K, Sieber M, Chaitowitz M, Braitman LE, Tester W, Diehl V. Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: A retrospective review of 1,114 patients. *Leuk Lymphoma* 2005;46:1715-20.
8. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Konstantinou N, Symeonidis A, Karmiris T, *et al.* Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease. *Haematologica* 2006;91:32-9.
9. Liao Z, Ha CS, Fuller LM, Hagemester FB, Cabanillas F, Tucker SL, *et al.* Subdiaphragmatic stage I and II Hodgkin's disease: Long-term follow-up and prognostic factors. *Int J Radiat Oncol Biol Phys* 1998;41:1047-56.
10. Cutuli B, Petit T, Hoffstetter S, Velten M, Dufour P, Giron C, *et al.* Treatment of subdiaphragmatic Hodgkin's disease: Long-term results and side effects. *Oncol Rep* 1998;5:1513-8.
11. van Dorp W, van Beek RD, Laven JS, Pieters R, de Muinck Keizer-Schrama SM, van den Heuvel-Eibrink MM. Long-term endocrine side effects of childhood Hodgkin's lymphoma treatment: A review. *Hum Reprod Update* 2012;18:12-28.